The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Rapivab
peramivir · PERAMIVIR 600 mg/60mL · Solution · Intravenous · BioCryst Pharmaceuticals, Inc.
NDC 72769-0181-03 · 3 VIAL, GLASS in 1 CARTON / 20 mL in 1 VIAL, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$950.00
Reported to Texas DSHS · 2026 annual filing · BioCryst Pharmaceuticals, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Alcami Carolinas CorporationUnited Statesanalysis
- Cilag AGSwitzerlandanalysis · api manufacture
- Eurofins Lancaster Laboratories, LLCUnited Statesanalysis
- analysis
- Jubilant HollisterStier LLCUnited Statesanalysis · label · manufacture · pack
- Patheon Manufacturing Services LLCUnited Statesanalysis · label · manufacture · pack
- Siegfried USA, LLCUnited Statesanalysis · api manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA206426
- TE code
- —
- Approval date
- Dec 19, 2014
- Patents / exclusivity
- 2 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 8778997 | May 7, 2027 |
| patent | 10391075 | Feb 12, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of peramivir (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Patheon Manufacturing Services LLC | PERAMIVIR 200 mg/20mL | Jul 15, 2026 | Sep 2, 2026 |
| BioCryst Pharmaceuticals, Inc. | PERAMIVIR 600 mg/60mL | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Rapivab — NDC 72769-0181-03," retrieved September 3, 2026, https://drugdashboards.com/drug/72769018103.
Free to cite with attribution — see how the data is put together.